サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：網膜疾患治療市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年
市場調査レポート
商品コード
1326472

網膜疾患治療市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年

Retinal Disorder Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Dosage Form, By Distribution Channel, By Region and Competition
出版日: | 発行: TechSci Research | ページ情報: 英文 112 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

網膜疾患治療市場- 世界の産業規模、シェア、動向、機会、予測、2018-2028年
出版日: 2023年08月01日
発行: TechSci Research
ページ情報: 英文 112 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 目次
概要

世界の網膜疾患治療市場は、網膜疾患の有病率の増加、人口の高齢化、ヘルスケア技術の進歩、医療費の増加などを背景に、予測期間中に目覚ましい成長が見込まれています。

人口の高齢化も網膜疾患治療市場を牽引する要因の一つです。高齢化に伴い、AMDや糖尿病性網膜症などの網膜疾患を発症するリスクが高まる。National Eye Instituteによると、AMDの有病率は50～59歳の2%から75歳以上では30%に増加します。世界の人口の高齢化に伴い、この動向は今後も続くと予想され、今後数年間は世界の網膜疾患治療市場の成長を支えることになります。

網膜疾患の有病率の増加

網膜疾患は、目の奥にある光感受性組織である網膜に影響を及ぼす疾患群です。これらの疾患は、軽度の視力障害から完全な失明まで、さまざまな症状を引き起こす可能性があり、世界的に視覚障害の主な原因となっています。世界保健機関（WHO）によると、世界中で推定2億5,300万人が視覚障害を抱えて生活しており、そのうち3,600万人が失明しています。加齢黄斑変性、糖尿病網膜症、網膜剥離などの疾患が視覚障害や失明の最も一般的な原因となっています。

加齢黄斑変性症（AMD）は網膜の進行性変性で、主に高齢者が罹患し、先進国における視覚障害の主な原因となっています。米国眼科学会によると、米国では推定1,100万人が何らかの形でAMDに罹患しており、その数は人口の高齢化に伴って増加すると予想されています。糖尿病の合併症である糖尿病網膜症は、網膜に進行性の障害を引き起こす可能性があり、世界的に視覚障害や失明のもう一つの一般的な原因となっています。国際糖尿病連合によると、世界中で推定4億6,300万人が糖尿病を患っており、その数は2045年までに7億人に増加すると予想されています。このうち3分の1までが糖尿病性網膜症を発症するリスクがあり、糖尿病患者の3人に1人はすでに何らかの視力低下を経験していると推定されています。網膜剥離や網膜色素変性症などの他の網膜疾患は、一般的ではありませんが、それでも人の視力や生活の質に大きな影響を与える可能性があります。網膜剥離は、網膜がその下の組織から剥がれるもので、約1万人に1人が罹患し、網膜色素変性症は、進行性の視力低下を引き起こす遺伝性疾患で、推定3,000～4,000人に1人が罹患しています。人口の間で網膜疾患の有病率が増加していることが治療需要の増加に寄与し、世界の網膜疾患治療市場の成長を牽引しています。

ヘルスケア技術の進歩

ヘルスケア技術の進歩が世界の網膜疾患治療市場を牽引しています。網膜疾患患者の予後を改善する新しい治療法や技術が登場しています。例えば、抗血管内皮増殖因子（抗VEGF）療法はAMD治療に革命をもたらし、病気の進行を遅らせ、視力を改善するのに役立っています。さらに、網膜インプラントや補助器具は、重度の視力低下を抱える患者に新たな選択肢を提供し、世界の網膜疾患治療市場の成長を支えています。

さらに、バーチャルリアリティ（VR）や拡張現実（AR）などの支援技術は、網膜疾患患者を支援するために開発されています。これらの技術は、視覚環境をシミュレートし、患者が周囲の環境をナビゲートするのに役立つフィードバックを提供することができます。例えば、VRヘッドセットは交通量の多い道路をシミュレートすることができ、患者は道路を安全に横断する練習ができます。これにより、今後数年間は世界の網膜疾患治療市場の成長に有利な機会が生まれると期待されています。

政府の支援策

網膜疾患は世界中で視覚障害や失明の主な原因となっており、あらゆる年齢層や人口構成の人々に影響を及ぼしています。網膜疾患には有効な治療法がいくつかありますが、これらの治療法へのアクセスは国や地域によって大きく異なります。米国、カナダ、西欧諸国の大部分などの先進国では、網膜疾患の治療は一般的に確立されており、広く利用可能です。しかし、発展途上諸国では、資源、インフラ、訓練を受けたヘルスケア専門家の不足により、網膜疾患治療へのアクセスが制限されることが多いです。こうした国々では網膜疾患を持つ多くの人々が必要な治療を受けることができず、視力低下や失明の発生率が高くなっています。

この格差に対処するため、発展途上国における網膜疾患治療へのアクセスを改善するための組織や政府のイニシアチブがいくつか設立されています。そのような取り組みのひとつが、2020年までに回避可能な失明をなくすことを目的とした世界保健機関（WHO）のビジョン2020プログラムです。このプログラムでは、網膜疾患に関連するものを含め、発展途上国における眼科医療サービスへのアクセスを改善することに重点が置かれていました。同様に中国でも、政府は網膜疾患を含む眼科医療サービスへのアクセスを改善するための全国的なプログラムを開始しました。このプログラムには、全国に300以上の眼科専門病院を設立することや、数千人の眼科医やその他の眼科医療専門家を育成することが含まれています。さらにインド政府は、十分なサービスを受けていない人々に無料または低コストの眼科医療サービスを提供するため、いくつかの国家プログラムを設立しました。これらのプログラムには、移動眼科診療所、遠隔医療サービス、白内障手術やその他の眼科手術の補助金などが含まれます。また、米国の国立眼科研究所は網膜疾患の研究に資金を提供し、患者やヘルスケア専門家にリソースを提供しています。さまざまな組織や政府によるこのような取り組みは、人々が効果的な網膜治療を受ける機会を増やし、世界の網膜疾患治療市場の成長を促進するでしょう。

利用可能なカスタマイズ

TechSci Researchでは、所定の市場データを用いて、企業固有のニーズに応じたカスタマイズを提供しています。レポートでは以下のカスタマイズが可能です：

企業情報

  • 追加市場参入企業（最大5社）の詳細分析とプロファイリング

目次

第1章 概要

  • 市場の定義
  • 市場の範囲
    • 対象市場
    • 調査対象年
    • 主要市場セグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の網膜疾患治療市場展望

  • 市場規模と予測
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 地域別
    • 企業別
  • 製品マップ
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 地域別

第6章 北米の網膜疾患治療薬市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 国別
  • 北米国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の網膜疾患治療市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋の網膜疾患治療市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の網膜疾患治療市場の展望

  • 市場規模・予測
    • 金額別
  • 市場シェアと予測
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの網膜疾患治療市場の展望

  • 市場規模・予測
    • 金額ベース
  • 市場シェアと予測
    • タイプ別
    • 剤形別
    • 流通チャネル別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の展開
  • 合併・買収
  • 製品上市

第13章 網膜疾患治療の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 競合情勢

  • Business Overview
  • Type Offerings
  • Recent Developments
  • Key Personnel
  • SWOT Analysis
    • Santen Pharmaceutical Co. Ltd.
    • Regeneron Pharmaceuticals Inc.
    • Graybug Vision, Inc.
    • Shire（Takeda Pharmaceutical Company Limited）
    • Bayer AG
    • Genentech, Inc.
    • Acucela Inc.
    • Pfizer, Inc.
    • Kubota Pharmaceutical Holdings Co., Ltd.
    • Allergan plc.（AbbVie Inc.）

第16章 戦略的提言

目次
Product Code: 14867

Global Retinal Disorder Treatment Market is expected to grow at an impressive rate during the forecast period on account of the increasing prevalence of retinal disorders, the aging population, advancements in healthcare technology, and rising healthcare expenditure, among others. The aging population is another factor driving the retinal disorder treatment market. As people age, their risk of developing retinal disorders such as AMD and diabetic retinopathy increases. According to the National Eye Institute, the prevalence of AMD increases from 2% in people aged 50-59 years to 30% in people aged 75 years and older. This trend is expected to continue as the global population ages, thereby supporting the growth of global retinal disorder treatment market for the next few years.

Additionally, increasing research and development activities by various companies operating in the market and academic & research institutions across the globe for the identification and development of new treatments for retinal disorders or to improve the safety and efficacy of existing treatments is expected to create lucrative opportunities for the growth of global retinal disorder treatment market during the forecast period. According to clinicaltrials.gov, as of March 2023, there are around 1,198 studies in different phases of development related to retinal disorders treatment across the globe.

Rising healthcare expenditure is another factor driving the global retinal disorder treatment market. As healthcare expenditure increases, more resources are being dedicated to the development and commercialization of new therapies and technologies for retinal disorders. According to the National Health Expenditure Account, total healthcare expenditure in the United States reached USD 3.8 trillion in 2019.

Growing Prevalence of Retinal Disorders

Retinal disorders are a group of conditions that affect the retina, the light-sensitive tissue at the back of the eye. These conditions can cause a range of symptoms, from mild vision impairment to complete blindness, and are a leading cause of visual impairment worldwide. According to the World Health Organization, an estimated 253 million people worldwide live with visual impairment, of whom 36 million are blind. Retinal disorders are a significant contributor to these numbers, with conditions such as age-related macular degeneration, diabetic retinopathy, and retinal detachment among the most common causes of visual impairment and blindness.

Age-related macular degeneration (AMD), a progressive degeneration of the retina that affects mostly older adults, is a leading cause of visual impairment in developed countries. According to the American Academy of Ophthalmology, an estimated 11 million people in the United States have some form of AMD, with that number expected to increase as the population ages. Diabetic retinopathy, a complication of diabetes that can cause progressive damage to the retina, is another common cause of visual impairment and blindness worldwide. According to the International Diabetes Federation, an estimated 463 million people worldwide have diabetes, with that number expected to rise to 700 million by 2045. Of these, up to one-third are at risk of developing diabetic retinopathy, with an estimated one in three people with diabetes already experiencing some form of vision loss. Other retinal disorders, such as retinal detachment and retinitis pigmentosa, are less common but can still have a significant impact on a person's vision and quality of life. Retinal detachment, a separation of the retina from the underlying tissue, affects approximately one in every 10,000 people, while retinitis pigmentosa, a genetic disorder that causes progressive vision loss, affects an estimated one in every 3,000 to 4,000 people. The increasing prevalence of retinal disorders among the population will contribute to an increase in demand for treatments, thereby driving the growth of global retinal disorder treatment market.

Advancements in Healthcare Technology

Advancements in healthcare technology are driving the global retinal disorder treatment market. New therapies and technologies are emerging that offer improved outcomes for patients with retinal disorders. For example, anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionized the treatment of AMD, helping to slow the progression of the disease and improve vision. Additionally, retinal implants and assistive devices are providing new options for patients with severe vision loss, in turn supporting the growth of global retinal disorder treatment market.

Additionally, assistive technologies such as virtual reality (VR) and augmented reality (AR) are being developed to help patients with retinal disorders. These technologies can simulate visual environments and provide feedback to help patients navigate their surroundings. For example, a VR headset can simulate a busy street, allowing patients to practice crossing the road safely. This, in turn, is expected to create lucrative opportunities for the growth of global retinal disorders treatment market in the next few years.

Supportive Government Initiatives

Retinal disorders are a major cause of visual impairment and blindness worldwide, affecting people of all ages and demographics. While there are several effective treatments available for retinal disorders, access to these treatments varies widely across different countries and regions. In developed countries such as the United States, Canada, and much of Western Europe, retinal disorder treatment is generally well-established and widely available. In developing countries, however, access to retinal disorder treatment is often limited by a lack of resources, infrastructure, and trained healthcare professionals. Many people with retinal disorders in these countries are unable to receive the care they need, leading to a higher incidence of vision loss and blindness.

To address this disparity, several organizations and government initiatives have been established to improve access to retinal disorder treatment in developing countries. One such initiative was the World Health Organization's Vision 2020 program, which aimed to eliminate avoidable blindness by the year 2020. The program focused on improving access to eye care services in developing countries, including those related to retinal disorders. Similarly, in China, the government has launched a nationwide program to improve access to eye care services, including those related to retinal disorders. The program includes the establishment of more than 300 specialized eye hospitals across the country, as well as the training of thousands of ophthalmologists and other eye care professionals. Additionally, in India, the government has established several national programs to provide free or low-cost eye care services to underserved populations. These programs include mobile eye clinics, telemedicine services, and subsidies for cataract surgery and other eye surgeries. Also, the National Eye Institute in the US funds research on retinal disorders and provides resources for patients and healthcare professionals. Such initiatives taken by different organizations and governments will increase the access of people to effective retinal treatment, thereby driving the growth of global retinal disorder treatment market.

Market Segmentation

Global Retinal Disorder Treatment Market can be segmented by type, dosage form, distribution channel, and by region. Based on type, Global Retinal Disorder Treatment market can be categorized into macular degeneration, diabetic retinopathy, and others. By dosage form, the Global Retinal Disorder Treatment market can be segmented into gels, eye solutions, capsules & tablets, eye drops, and others. By distribution channel, the Global Retinal Disorder Treatment market can be fragmented into hospital pharmacies, online pharmacy, and retail pharmacies. Regionally, the global Retinal Disorder Treatment market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Santen Pharmaceutical Co. Ltd., Regeneron Pharmaceuticals Inc., Graybug Vision, Inc., Shire (Takeda Pharmaceutical Company Limited), Bayer AG, Genentech, Inc., Acucela Inc., Pfizer, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Allergan plc. (AbbVie Inc.), among others, are some of the leading players operating in the global Retinal Disorder Treatment market.

Recent Developments

  • In 2017, the U.S. Food and Drug Administration approved the first gene therapy for an inherited retinal disorder called Leber congenital amaurosis. This therapy, called Luxturna, uses a virus to deliver a healthy copy of a defective gene to the retina, which can improve vision in people with the disorder. Since then, several other gene therapies for retinal disorders have been tested in clinical trials with promising results.
  • In 2019, a team of researchers at the University of California, Los Angeles, announced that they had successfully used stem cells to restore vision in mice with retinal degeneration. The researchers hope to begin human clinical trials in the near future.
  • In 2019, the U.S. Food and Drug Administration approved a new drug called Beovu for the treatment of wet age-related macular degeneration, a common retinal disorder that can lead to vision loss. Beovu works by targeting a protein called VEGF, which can cause abnormal blood vessel growth in the retina. The drug has been shown to be effective at reducing the progression of the disease and improving vision in people with wet age-related macular degeneration.

Report Scope:

In this report, Global Retinal Disorder Treatment Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Retinal Disorder Treatment Market, By Type:

  • Macular Degeneration
  • Diabetic Retinopathy
  • Others

Retinal Disorder Treatment Market, By Dosage Form:

  • Gels
  • Eye Solution
  • Capsules & Tablets
  • Eye Drops
  • Others

Retinal Disorder Treatment Market, By Distribution Channel:

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Retinal Disorder Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Retinal Disorder Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Retinal Disorder Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Macular Degeneration, Diabetic Retinopathy, Others)
    • 5.2.2. By Dosage Form (Gels, Eye Solution, Capsules & Tablets, Eye Drops, Others)
    • 5.2.3. By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
    • 5.2.4. By Region
    • 5.2.5. By Company (2022)
  • 5.3. Product Map
    • 5.3.1. By Type
    • 5.3.2. By Dosage Form
    • 5.3.3. By Distribution Channel
    • 5.3.4. By Region

6. North America Retinal Disorder Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Dosage Form
    • 6.2.3. By Distribution Channel
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Retinal Disorder Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Dosage Form
        • 6.3.1.2.3. By Distribution Channel
    • 6.3.2. Canada Retinal Disorder Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Dosage Form
        • 6.3.2.2.3. By Distribution Channel
    • 6.3.3. Mexico Retinal Disorder Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Dosage Form
        • 6.3.3.2.3. By Distribution Channel

7. Europe Retinal Disorder Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Dosage Form
    • 7.2.3. By Distribution Channel
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Retinal Disorder Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Dosage Form
        • 7.3.1.2.3. By Distribution Channel
    • 7.3.2. Germany Retinal Disorder Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Dosage Form
        • 7.3.2.2.3. By Distribution Channel
    • 7.3.3. United Kingdom Retinal Disorder Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Dosage Form
        • 7.3.3.2.3. By Distribution Channel
    • 7.3.4. Italy Retinal Disorder Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Dosage Form
        • 7.3.4.2.3. By Distribution Channel
    • 7.3.5. Spain Retinal Disorder Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Dosage Form
        • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Retinal Disorder Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Dosage Form
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Retinal Disorder Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Dosage Form
        • 8.3.1.2.3. By Distribution Channel
    • 8.3.2. India Retinal Disorder Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Dosage Form
        • 8.3.2.2.3. By Distribution Channel
    • 8.3.3. Japan Retinal Disorder Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Dosage Form
        • 8.3.3.2.3. By Distribution Channel
    • 8.3.4. South Korea Retinal Disorder Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Dosage Form
        • 8.3.4.2.3. By Distribution Channel
    • 8.3.5. Australia Retinal Disorder Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Dosage Form
        • 8.3.5.2.3. By Distribution Channel

9. South America Retinal Disorder Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Dosage Form
    • 9.2.3. By Distribution Channel
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Retinal Disorder Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Dosage Form
        • 9.3.1.2.3. By Distribution Channel
    • 9.3.2. Argentina Retinal Disorder Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Dosage Form
        • 9.3.2.2.3. By Distribution Channel
    • 9.3.3. Colombia Retinal Disorder Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Dosage Form
        • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Retinal Disorder Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Dosage Form
    • 10.2.3. By Distribution Channel
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Retinal Disorder Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Dosage Form
        • 10.3.1.2.3. By Distribution Channel
    • 10.3.2. Saudi Arabia Retinal Disorder Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Dosage Form
        • 10.3.2.2.3. By Distribution Channel
    • 10.3.3. UAE Retinal Disorder Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Dosage Form
        • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Type Launches

13. Global Retinal Disorder Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Types

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Type Offerings
  • 15.3. Recent Developments
  • 15.4. Key Personnel
  • 15.5. SWOT Analysis
    • 15.5.1. Santen Pharmaceutical Co. Ltd.
    • 15.5.2. Regeneron Pharmaceuticals Inc.
    • 15.5.3. Graybug Vision, Inc.
    • 15.5.4. Shire (Takeda Pharmaceutical Company Limited)
    • 15.5.5. Bayer AG
    • 15.5.6. Genentech, Inc.
    • 15.5.7. Acucela Inc.
    • 15.5.8. Pfizer, Inc.
    • 15.5.9. Kubota Pharmaceutical Holdings Co., Ltd.
    • 15.5.10. Allergan plc. (AbbVie Inc.)

16. Strategic Recommendations